Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV

• Published in: PloS one 2021-05, Vol.16 (5), p.e0251552-e0251552
• Main Authors: Pan, Calvin Q, Chang, Ting-Tsung, Bae, Si Hyun, Brunetto, Maurizia, Seto, Wai-Kay, Coffin, Carla S, Tan, Susanna K, Mo, Shuyuan, Flaherty, John F, Gaggar, Anuj, Nguyen, Mindie H, Çelen, Mustafa Kemal, Thompson, Alexander, Gane, Edward J
• Format: Article
• Language: English
• Subjects: Alanine; Alanine transaminase; Analysis; Antigens; Antiretroviral drugs; Antiviral drugs; Biological response modifiers; Biology and life sciences; Care and treatment; Chronic infection; Clinical trials; Complications and side effects; Deoxyribonucleic acid; Disease prevention; DNA; Editing; FDA approval; Health care facilities; Health risks; Hepatitis; Hepatitis B; Hepatitis B surface antigen; Hepatocytes; Hospitals; Infections; Intracellular levels; Kinetics; Liver; Liver diseases; Liver transplantation; Magnetohydrodynamic stability; Medicine; Medicine and health sciences; Patient outcomes; People and Places; Pregnancy; Research and Analysis Methods; Risk analysis; Risk factors; Tenofovir; Vaccines; Viruses; Womens health
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0251552

Use of tenofovir disoproxil fumarate (TDF) improves patient outcomes in preventing mother-to-child transmission (pMTCT) of the hepatitis B virus (HBV) in mothers with chronic HBV and high viral loads. Given the lack of data for tenofovir alafenamide (TAF) in pMTCT, rates of early viral suppression with TAF and TDF were evaluated in women of childbearing potential (WOCBP) participating in 2 randomized, double-blind, Phase 3 studies in chronic HBV. In a patient subset meeting WOCBP criteria and with baseline HBV DNA >200,000 IU/mL, rates of viral suppression with TAF or TDF in achieving the target of HBV DNA